In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 5, 2010, Pages 336-347

  Yang, Wei ^a   Chow, Keat Theng ^a   Lang, Bo ^a   Wiederhold, Nathan P ^a,b   Johnston, Keith P ^c   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c The University of Texas at Austin   (United States)

Author keywords

Aerosol; Cyclodextrin; Nanoparticle; Permeability across mucosal membrane; Poorly water soluble drug; Pulmonary delivery

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ITRACONAZOLE; NANOPARTICLE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COLLOID; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TISSUE LEVEL; FREEZE DRYING; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG ALVEOLUS EPITHELIUM; LUNG WEIGHT; MALE; MOUSE; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; SINGLE DRUG DOSE; SOLID STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY PHOTOELECTRON SPECTROSCOPY;

AEROSOLS; ANIMALS; ANTIFUNGAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLODEXTRINS; ITRACONAZOLE; LUNG; MALE; MICE; PARTICLE SIZE; SOLUTIONS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 77549085772     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.01.001     Document Type: Article

References (82)

1. Al-Marzouqi A.H., Elwy H.M., Shehadi I., and Adem A. Physicochemical properties of antifungal drug-cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques. J. Pharm. Biomed. Anal. 49 (2009) 227-233
2. Al-Marzouqi A.H., Shehatta I., Jobe B., and Dowaidar A. Phase solubility and inclusion complex of itraconazole with beta-cyclodextrin using supercritical carbon dioxide. J. Pharm. Sci. 95 (2006) 292-304
3. Alvarez C.A., Wiederhold N.P., McConville J.T., Peters J.I., Najvar L.K., Graybill J.R., Coalson J.J., Talbert R.L., Burgess D.S., Bocanegra R., Johnston K.P., and Williams III R.O. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect. 55 (2007) 68-74
4. Barone J.A., Koh J.G., Bierman R.H., Colaizzi J.L., Swanson K.A., Gaffar M.C., Moskovitz B.L., Mechlinski W., and Vandevelde V. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male-volunteers. Antimicrob. Agents Chemother. 37 (1993) 778-784
5. Bradford C.R., Prentice A.G., Warnock D.W., and Copplestone J.A. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J. Antimicrob. Chemother. 28 (1991) 555-560
6. Brewster M.E., and Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Delivery Rev. 59 (2007) 645-666
7. Brewster M.E., Neeskens P., and Peeters J. Solubilization of itraconazole as a function of cyclodextrin structural space. J. Inclusion Phenom. Macrocyclic Chem. 57 (2007) 561-566
8. Brewster M.E., Noppe M., Peeters J., and Loftsson T. Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int. J. Pharm. 342 (2007) 250-253
9. Brewster M.E., Simpkins J.W., Hora M.S., Stern W.C., and Bodor N. The potential use of cyclodextrins in parenteral formulations. J. Parenter. Sci. Technol. 43 (1989) 231-240
10. Brewster M.E., Vandecruys R., Peeters J., Neeskens P., Verreck G., and Loftsson T. Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions. Eur. J. Pharm. Sci. 34 (2008) 94-103
11. Byron P., and Phillips E. Absorption, clearance and dissolution in the lung. In: Byron P.R. (Ed). Respiratory Drug Delivery (1990), CRC, Boca Raton, FL
12. Byron P.R., and Patton J.S. Drug delivery via the respiratory tract. J. Aerosol Med. 7 (1994) 49-75
13. Clark T.A., and Hajjeh R.A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 15 (2002) 569-574
14. Dahlberg C., Millqvist-Fureby A., and Schuleit M. Surface composition and contact angle relationships for differently prepared solid dispersions. Eur. J. Pharm. Biopharm. 70 (2008) 478-485
15. De Beule K., and Van Gestel J. Pharmacology of itraconazole. Drugs 61 (2001) 27-37
16. Echezarreta-Lopez M., Torres-Labandeira J.J., Castineiras-Seijo L., Santana-Penin L., and Vila-Jato J.L. Complexation of the interferon inducer, bropirimine, with hydroxypropyl-beta-cyclodextrin. Eur. J. Pharm. Sci. 9 (2000) 381-386
17. Elder E.J., Hitt J.E., Rogers T.L., Tucker C.J., Saghir S., Kupperblatt G.B., Svenson S., and Evans J.C. Particle engineering of poorly water soluble drugs by controlled precipitation. ACS Symp. Ser. 924 (2006) 292-304
18. Forbes B., and Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur. J. Pharm. Biopharm. 60 (2005) 193-205
19. Geelhaar A., and Weibel E.R. Morphometric estimation of pulmonary diffusion capacity. 3. The effect of increased oxygen consumption in Japanese Waltzing mice. Resp. Physiol. 11 (1971) 354-366
20. Geiser M., and Bastian S. Surface-lining layer of airways in cystic fibrosis mice. Am. J. Physiol.-Lung C 285 (2003) L1277-L1285
21. Geiser M., Hof V.I., Siegenthaler W., Grunder R., and Gehr P. Ultrastructure of the aqueous lining layer in hamster airways: is there a two-phase system?. Microsc. Res. Tech. 36 (1997) 428-437
22. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1408 (1998) 79-89
23. Heykants J., Vanpeer A., Vandevelde V., Vanrooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., Vancutsem J., and Cauwenbergh G. The clinical pharmacokinetics of itraconazole - an overview. Mycoses 32 (1989) 67-87
24. Hoeben B.J., Burgess D.S., McConville J.T., Najvar L.K., Talbert R.L., Peters J.I., Wiederhold N.P., Frei B.L., Graybill J.R., Bocanegra R., Overhoff K.A., Sinswat P., Johnston K.P., and Williams R.O. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50 (2006) 1552-1554
25. Hong J.Y., Kim J.K., Song Y.K., Park J.S., and Kim C.K. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Control. Release 110 (2006) 332-338
26. Hostetler J.S., Hanson L.H., and Stevens D.A. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother. 36 (1992) 477-480
27. Hostetler J.S., Hanson L.H., and Stevens D.A. Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis. J. Antimicrob. Chemother. 32 (1993) 459-463
28. Irie T., and Uekama K. Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation. J. Pharm. Sci. 86 (1997) 147-162
29. Jacobs C., and Muller R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19 (2002) 189-194
30. Jones S., and Parr G. The acetotoluides as models for studying cyclodextrin inclusion complexes. Int. J. Pharm. 36 (1987) 223-231
31. Khanvilkar K., Donovan M.D., and Flanagan D.R. Drug transfer through mucus. Adv. Drug Deliver. Rev. 48 (2001) 173-193
32. Koushik K., Dhanda D.S., Cheruvu N.P., and Kompella U.B. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm. Res. 21 (2004) 1119-1126
33. Kraft W.K., Steiger B., Beussink D., Quiring J.N., Fitzgerald N., Greenberg H.E., and Waldman S.A. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J. Clin. Pharmacol. 44 (2004) 67-72
34. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., and Liolios L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50 (2006) 2946-2950
35. Lindmark T., Kimura Y., and Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284 (1998) 362-369
36. Liu F.Y., Shao Z., Kildsig D.O., and Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 10 (1993) 228-232
37. Loftsson T., and Masson M. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J. Drug Deliv. Sci. Tech. 14 (2004) 35-43
38. Loftsson T., Masson M., and Sigurjonsdottir J.F. Methods to enhance the complexation efficiency of cyclodextrins. STP Pharma Sci. 9 (1999) 237-242
39. Loftsson T., Vogensen S.B., Brewster M.E., and Konrá{eth}sdóttir F. Effects of cyclodextrins on drug delivery through biological membranes. J. Pharm. Sci. 96 10 (2007) 2532-2546
40. Marques H.M.C., Hadgraft J., and Kellaway I.W. Studies of cyclodextrin inclusion complexes. 1. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int. J. Pharm. 63 (1990) 259-266
41. Marques H.M.C., Hadgraft J., Kellaway I.W., and Taylor G. Studies of cyclodextrin inclusion complexes. 3. The pulmonary absorption of beta-cyclodextrin. Dm-beta-cyclodextrin and Hp-beta-cyclodextrin in rabbits. Int. J. Pharm. 77 (1991) 297-302
42. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34 (2002) 909-917
43. Matilainen L., Toropainen T., Vihola H., Hirvonen J., Jarvinen T., Jarho P., and Jarvinen K. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J. Controlled Release 126 (2008) 10-16
44. Matteucci M.E., Brettmann B.K., Rogers T.L., Elder E.J., Williams R.O., and Johnston K.P. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol. Pharm. 4 (2007) 782-793
45. McConville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., Talbert R.L., Peters J.I., Johnston K.P., and Williams III R.O. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 23 (2006) 901-911
46. Miller D.A., DiNunzio J.C., Yang W., McGinity J.W., and Williams R.O. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm. Res. 25 (2008) 1450-1459
47. Miller D.A., McConville J.T., Yang W., Williams III R.O., and McGinity J.W. Hot-melt extrusion for enhanced delivery of drug particles. J. Pharm. Sci. 96 (2007) 361-376
48. Miyake K., Irie T., Arima H., Hirayama F., Uekama K., Hirano M., and Okamaoto Y. Characterization of itraconazole/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution. Int. J. Pharm. 179 (1999) 237-245
49. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Delivery Rev. 47 (2001) 3-19
50. Nesseem D.I. Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. J. Pharm. Biomed. Anal. 26 (2001) 387-399
51. Niven R.W. Pharmaceutical Inhalation Aerosol Technology (1992), Marcel Dekker, Inc., New York
52. Oh D.M., Curl R.L., and Amidon G.L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans - a mathematical-model. Pharm. Res. 10 (1993) 264-270
53. Ostrander K.D., Bosch H.W., and Bondanza D.M. An in-vitro assessment of a NanoCrystal (TM) beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 48 (1999) 207-215
54. Park M.J., Ren S., and Lee B.J. In vitro and in vivo comparative study of itiraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Biopharm. Drug Dispos. 28 (2007) 199-207
55. Patterson T.F. Advances and challenges in management of invasive mycoses. Lancet 366 (2005) 1013-1025
56. Patton J. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Delivery Rev. 19 (1996) 3-36
57. Patton J., Fishburn C., and Weers J. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1 (2004) 338-344
58. Patton J.S., and Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. 6 (2007) 67-74
59. Peeters J., Neeskens P., Tollenaere J.P., Van Remoortere P., and Brewster M.E. Characterization of the Interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 91 (2002) 1414-1422
60. Pitha J., Szente L., and Szejtli J. Molecular encapsulation of drugs by cyclodextrins and congeners. In: Bruck S.D. (Ed). Controlled Drug Delivery (1983), CRC Press, Inc., Boca Raton, FL
61. Poirier J.M., and Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. 35 (1998) 461-473
62. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85 (1996) 1142-1169
63. Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., Lancaster M., Odds F.C., Rinaldi M.G., Walsh T.J., and Barry A.L. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24 (1997) 235-247
64. Shao Z.H., Li Y.P., Chermak T., and Mitra A.K. Cyclodextrins as mucosal absorption promoters of insulin. 2. Effects of beta-cyclodextrin derivatives on alpha-chymotryptic degradation and enteral absorption of insulin in rats. Pharm. Res. 11 (1994) 1174-1179
65. Shehatta I., Al-Marzouqi A., Jobe B., and Dowaidar A. Enhancement of aqueous solubility of itraconazole by complexation with cyclodextrins using supercritical carbon dioxide. Can. J. Chem. 83 (2005) 1833-1838
66. Six K., Daems T., de Hoon J., Van Hecken A., Depre M., Bouche M.P., Prinsen P., Verreck G., Peeters J., Brewster M.E., and Van den Mooter G. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur. J. Pharm. Sci. 24 (2005) 179-186
67. Sobel J.D. Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America. Clin. Infect. Dis. 30 (2000) 652
68. ®, p.l. Package insert. Sporanox capsules/oral solution/Sporanox I.V. (itraconazole).
69. Stella V.J., and He Q. Cyclodextrins. Toxicol. Pathol. 36 (2008) 30-42
70. Stella V.J., Rao V.M., Zannou E.A., and Zia V. Mechanisms of drug release from cyclodextrin complexes. Adv. Drug Delivery Rev. 36 (1999) 3-16
71. Stevens D.A. Itraconazole in cyclodextrin solution. Pharmacotherapy 19 (1999) 603-611
72. Thiel M.A., Zinkernagel A.S., Burhenne J., Kaufmann C., and Haefeli W.E. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob. Agents Chemother. 51 (2007) 239-244
73. Tolman J.A., Nelson N.A., Son Y.J., Bosselmann S., Wiederhold N.P., Peters J.I., McConville J.T., and Williams III R.O. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur. J. Pharm. Biopharm. 72 (2009) 199-205
74. USP, 2008. Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhalers USP 31-NF 26. The United States Pharmacopeial Convention. Rockville, MD.
75. +, and albumin concentrations in the alveolar milieu of normal humans and pulmonary sarcoidosis patients. Am. Rev. Respir. Dis. 143 (1991) 1096-1101
76. Vaughn J.M., Gao X., Yacaman M.J., Johnston K.P., and Williams III R.O. Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using novel Z-contrast STEM and complimentary techniques. Eur. J. Pharm. Biopharm. 60 (2005) 81-89
77. Vaughn J.M., McConville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., and Williams III R.O. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 63 (2006) 95-102
78. Wall D.A., Marcello J., Pierdomenico D., and Farid A. Administration as hydroxypropyl-beta-cyclodextrin complexes does not slow rates of pulmonary drug absorption in rat. STP Pharma Sci. 4 (1994) 63-68
79. Willems L., van der Geest R., and de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 26 (2001) 159-169
80. Yang W., Peters J.I., and Williams R.O. Inhaled nanoparticles - a current review. Int. J. Pharm. 356 (2008) 239-247
81. Yang W., Tam J., Miller D.A., Zhou J., McConville J.T., Johnston K.P., and Williams R.O. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int. J. Pharm. 361 (2008) 177-188
82. Yang W., Wiederhold N.P., and Williams III R.O. Drug delivery strategies for improved azole antifungal action. Expert Opin. Drug Deliv. 5 (2008) 1199-1216